Based on the provided sources, there is limited information available regarding the safety of lurbinectedin for pregnant women. The sources primarily focus on the drug's patent information, FDA label, and clinical trials.
The first source, Drug Patent Watch, provides information on the patent status of lurbinectedin but does not specifically address its safety during pregnancy. Therefore, this source does not directly answer the question.
The second source, the FDA label for lurbinectedin, provides important information about the drug's usage, indications, and potential side effects. However, it does not mention anything about the safety of lurbinectedin during pregnancy.
The third source, the National Cancer Institute's clinical trials database, provides information about ongoing clinical trials involving lurbinectedin. While this source may provide valuable information on the drug's efficacy and potential side effects, it does not specifically address the safety of lurbinectedin for pregnant women.
Given the lack of specific information on the safety of lurbinectedin for pregnant women in the provided sources, it is important to consult with a healthcare professional or a medical expert who can provide personalized advice based on the latest research and clinical guidelines. They will be able to assess the potential risks and benefits of using lurbinectedin during pregnancy and provide appropriate guidance.
In conclusion, based on the provided sources, there is insufficient information to determine the safety of lurbinectedin for pregnant women. It is crucial to consult with a healthcare professional for personalized advice and guidance regarding the use of lurbinectedin during pregnancy.
Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from: https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] FDA. Lurbinectedin FDA Label. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] National Cancer Institute. Clinical Trials: NCI-2021-12410. Retrieved from: https://www.cancer.gov/clinicaltrials/NCI-2021-12410